Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
Second Affiliated Hospital, School of Medicine, Zhejiang University
66 participants
Jun 2, 2025
INTERVENTIONAL
Conditions
Summary
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
Eligibility
Inclusion Criteria5
- Adults aged 18 to 75 years.
- Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m².
- Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months.
- Able and willing to comply with study procedures and complete follow-up assessments.
- Provide written informed consent.
Exclusion Criteria8
- Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism).
- Use of anti-obesity medications or participation in another weight-loss program within the past 3 months.
- Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy.
- History of pancreatitis, severe gastrointestinal disease, or bariatric surgery.
- Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation.
- Pregnant or breastfeeding women, or women planning pregnancy during the study period.
- Current participation in any other clinical trial.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Semaglutide administered once weekly by subcutaneous injection.Dose titrated from 0.25 mg to 2.0 mg as tolerated over 24 weeks
Tirzepatide administered once weekly by subcutaneous injection. Dose titrated from 2.5 mg to 10 mg as tolerated over 24 weeks
Metformin administered orally. Dose titrated from 500 mg to 1500-2000 mg daily, based on tolerance, for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07293325